Price Chart
Insider Transactions
| Date | Insider | Dir. | Shares | Value |
|---|---|---|---|---|
| Aug 24, 2026 | Stewart, Thomas Carlton | Sell | 5,768 | — |
| Aug 24, 2026 | Stewart, Thomas Carlton | Buy | 5,768 | — |
| Aug 24, 2026 | Stewart, Thomas Carlton | Buy | 2,231 | $3K |
| Aug 24, 2026 | Gedeon, Christelle | Sell | 30,312 | — |
| Aug 24, 2026 | Gedeon, Christelle | Buy | 30,312 | — |
| Aug 24, 2026 | Gedeon, Christelle | Buy | 13,344 | $20K |
Score uses open-market buys only
· 2 open-market
· 2 plan / compensation shown but not scored
· Return is unrealized, to today's price; a
“· Nd” mark means the 90-day window is still open (N of 90 days) — too early to judge.
Score Breakdown
| Component | Points | Max |
|---|---|---|
| Conviction (unique buyers) ✓ FREE PREVIEW | 25 | 30 |
| Buy/sell ratio | 20 | |
| Dollar value | 25 | |
| Lobbying activity | 15 | |
| Contract wins | 10 | |
| Insider track record | 10 | |
| Private placements | 8 | |
| Confluence bonus | 10 | |
| Cluster timing (velocity) | 10 | |
| Buy/sell reversal pattern | 8 | |
| Total | 40 | 100 |
Buying Insiders
| Insider | Credibility | Buy Value (90d) |
|---|---|---|
| Gedeon, Christelle | — | $20K |
| Stewart, Thomas Carlton | — | $3K |
Credibility score: historical hit rate × avg 90d return × sample size.
View full insider leaderboard →
Lobbying Registrations
No active OCL lobbying registrations in the last 90 days.
Analyst plan →
Government Contract Wins
No government contract wins in the last 90 days.
Analyst plan →
Private Placements
Private placement history, deal size, and lock-up expiry tracking.
Analyst plan →
Indigenous Consultation
No Indigenous consultation records on file for WEED.
SEDAR+ Filings
Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes.
Search SEDAR+ →
Short Interest
Shares short
15,229,287
Net change
-1,108,031
(-6.8%)
History
Sep 30:
15,229,287
Sep 15:
16,337,318
Aug 31:
15,196,659
Aug 15:
15,361,079
Jul 31:
17,067,396
Jul 15:
16,762,332
Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).
Wikipedia Attention
Views (30d)
1,898
Daily English-Wikipedia pageviews (Wikimedia). Traffic spikes often coincide with news — a
public-attention indicator, not investment advice.
Clinical Trials
| Phase | Status | Trial |
|---|---|---|
| P1/P2 | Completed | A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and |
| P2 | Completed | The Effects of CBD Isolate on Menstrual-Related Symptoms |
| P1 | Completed | Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of |
| P2 | Completed | Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Su |
| P2 | Completed | A Randomized Controlled Test of the Effects of CHI-554 on Fear. |
| P1 | Terminated | CBD in Postmenopausal Women With Osteopenia |
| — | Unknown | Canadian Registry for the Use of Spectrum Therapeutics Cannabis Produc |
| P2 | Terminated | CHI-907 CBD Extract and Experiences of Test Anxiety |
| P2 | Terminated | Investigation of the Efficacy and Safety of CHI-921 in Insomnia. |
| P2 | Withdrawn | CHI-902 for Treatment of Social Anxiety Disorder |
Trials where this company is the lead sponsor (ClinicalTrials.gov). Phase advances, completions and
terminations are material catalysts for clinical-stage companies — not investment advice.
Boardroom Connections
| Insider | Other boards | Also an insider at |
|---|---|---|
| Atkins, Margaret Shan | 1 | ACB (10) |
| Yanofsky, Terry | 1 | RET (45) |
People who file as insiders here and at other TSX/TSXV companies (number in brackets = that company's
Confluence Score). A well-connected insider taking a seat at a new junior can be an early tell. Matched by
name across SEDI filings; funds and 10%+ holders excluded.